SWA
VIR icon

Sutton Wealth Advisors’s Vir Biotechnology VIR Stock Holding History

Sutton Wealth Advisors’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,266
Closed -$32K – 1546
2022
Q4 		$32K Buy
1,266
+602
+91% +$14.8K 0.01% 527
2022
Q3 		$12.8K Sell
664
-833
-56% -$21.2K 0.01% 818
2022
Q2 		$38.1K Buy
+1,497
New +$35K 0.02% 454

Other funds holding VIR

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
GF
Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return

Sutton Wealth Advisors's VIR Position: Q1 2023 in Review

Sutton Wealth Advisors sold out of Vir Biotechnology (VIR) in Q1 2023, closing a stake of 1,266 shares — an estimated $32K sold.

Sutton Wealth Advisors first reported a position in VIR in Q2 2022 and held it in 3 quarters. The position peaked at $38.1K in Q2 2022. 232 funds tracked by Wall St. Rank hold VIR as of Q1 2023.

  • Sutton Wealth Advisors reported no remaining Vir Biotechnology position as of Q1 2023 after selling out during the quarter.
  • Sutton Wealth Advisors sold 1,266 Vir Biotechnology shares in Q1 2023, an estimated $32K.
  • Sutton Wealth Advisors first reported a position in Vir Biotechnology in Q2 2022 and held it in 3 quarters.
  • Sutton Wealth Advisors's Vir Biotechnology position peaked at $38.1K in Q2 2022.
  • 232 funds tracked by Wall St. Rank held Vir Biotechnology as of Q1 2023.

Based on Sutton Wealth Advisors's 13F filing for Q1 2023, filed 7 Nov 2023.